Takeda Pharmaceutical’s soticlestat did not meet Phase 3 goals in Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy. But the pharma giant points to results on secondary goals and subgroup analyses, and plans to discuss with regulators the “totality of data.”
Ovid Therapeutics is acquiring global rights to AstraZeneca molecules that address a novel target to treat epilepsy. The AstraZeneca deal comes 10 months after Takeda Pharmaceutical paid $196 million up front to acquire Ovid’s rights to a Phase 3 ready molecule for two rare forms of epilepsy.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Takeda Pharmaceutical gains full rights to a small molecule that has shown promise treating seizures in several rare forms of epilepsy. Meanwhile, Ovid Therapeutics gains cash to support its pipeline of neurological disease drug candidates.
The data from a Phase II pilot and an extension study of soticlestat, also known as OV935 or TAK-935, showed short- and long-term reductions of seizure frequency in patients with CDKL5 deficiency disorder and Dup15q syndrome.
In an open letter published by BIO, the executives emphasized the importance of science-driven evaluation of medicines and regulatory independence. The letter came amid growing concern about political pressure over the FDA, as well as lack of diversity in trials and companies being too quick to announce data that are inconclusive.
In exchange for a $20 million upfront payment and up to $212.5 million in milestones, Italy-based Angelini will gain exclusive development, manufacturing and commercialzation rights in Europe for OV101, a drug for Angelman syndrome.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science.
The trial's primary endpoint will be one for which the drug, OV101, produced encouraging but mixed results in a Phase II study of patients with Angelman syndrome.
The industry should also not be shy about going after actors who increase prices on drugs without increasing value, said the chair, Jeremy Levin, who is CEO of Ovid Therapeutics.
A group of biotech executives, entrepreneurs, academics and researchers has sent an open letter to President Trump arguing that if DACA is not preserved, the economy (and by association the biotech industry) stands to lose and bigly.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Stealth New York-based startup Ovid Therapeutics just raised $5 million, according to a regulatory filing. CEO Matthew During, an accomplished neuroscientist, declined to comment on the fundraise, though he told me last week that some interesting announcements are forthcoming. In the meantime, here are some bits and pieces from which we can draw conjecture: The company’s chairman […]